Fortunately, in some instances, identification of new targets has revolutionized the therapeutic management of sarcoma patients, as illustrated by the use of imatinib mesylate targeting receptor tyrosine kinases in GIST even if secondary resistance is observed (Napolitano & Vincenzi, 2019), which can be overcome with other, rationally designed TKIs (Blay et al, 2020). This evidence concerns the gene NTRK1 and sarcoma.